News

Public · Published

SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

SELLAS Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached the pre-specified 80th event, the number of deaths. This triggers database lock, unblinding and final analysis, with topline primary endpoint results expected this quarter.

Published:

Updated:

What happened

SELLAS Life Sciences said its Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached the pre-specified 80th event, the number of deaths. This triggers database lock, unblinding and final analysis, with topline primary endpoint results expected this quarter.

Confirmed

Global impact / market context

This trial result is a key decision point for SELLAS, because success or failure can reshape how investors value the company's lead treatment and its ability to fund further development of galinpepimut-S, which means the drug candidate being tested.

Analyst inference

The company says AML patients in second complete remission have limited treatment options. A positive overall survival result could support regulatory talks and partnerships, while a negative result would likely reduce expectations for this program and make future financing harder.

Analyst inference

What to watch

  1. The company plans to announce preliminary topline primary endpoint results this quarter, following database lock, unblinding and statistical analysis under the study's pre-specified statistical analysis plan, which means the pre-set rules for analyzing the data. Confirmed
  2. Watch whether the reported overall survival result meets the trial's pre-specified statistical goal, and whether SELLAS discloses the size of the survival benefit and any safety findings from the unblinded data. Proposed
  3. Track how the result affects SELLAS's ability to raise cash or find a partner, since a late-stage trial outcome can change spending plans, borrowing costs and investor positioning in the stock. Analyst inference

Evidence